Cas:54716-29-9 ethyl 2-(propan-2-ylideneamino)oxypropanoate manufacturer & supplier

Chemical Name:ethyl 2-(propan-2-ylideneamino)oxypropanoate

CAS.NO:54716-29-9

Synonyms:ethyl 2-(propan-2-ylideneamino)oxypropanoate

Molecular Formula:C₈H₁₅NO₃

Molecular Weight:173.21000

HS Code:2925290090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:213ºC at 760 mmHg

Density:1g/cm3

Index of Refraction:1.437

PSA:47.89000

Exact Mass:173.10500

LogP:1.35040

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like ethyl 2-(propan-2-ylideneamino)oxypropanoate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,ethyl 2-(propan-2-ylideneamino)oxypropanoate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,ethyl 2-(propan-2-ylideneamino)oxypropanoate Use and application,ethyl 2-(propan-2-ylideneamino)oxypropanoate technical grade,usp/ep/jp grade.

Related News: One key question for the fixed-duration combo is whether it can sustain remission after treatment has stopped. In the preliminary analysis of the GLOW trial, at three months after treatment ended, 51.9% of the Imbruvica-Venclexta patients had undetectable measurable residual disease (uMRD)—a stringent marker reflecting no signs of cancer—in bone marrow, versus 17.1% for the control group. The rates for peripheral blood were 54.7% and 39% for the two groups, respectively. ethyl 2-(propan-2-ylideneamino)oxypropanoate manufacturer The upstream industry for the R & D, production and sales of pharmaceutical intermediates is the basic chemical raw material industry, and the downstream industry is the chemical bulk drug and chemical pharmaceutical preparation industry. ethyl 2-(propan-2-ylideneamino)oxypropanoate supplier The active ingredient (AI) is the substance or substances that are biologically active within the drug and is the specific component responsible for the desired effect it has on the individual taking it. ethyl 2-(propan-2-ylideneamino)oxypropanoate vendor One key question for the fixed-duration combo is whether it can sustain remission after treatment has stopped. In the preliminary analysis of the GLOW trial, at three months after treatment ended, 51.9% of the Imbruvica-Venclexta patients had undetectable measurable residual disease (uMRD)—a stringent marker reflecting no signs of cancer—in bone marrow, versus 17.1% for the control group. The rates for peripheral blood were 54.7% and 39% for the two groups, respectively. ethyl 2-(propan-2-ylideneamino)oxypropanoate factory The upstream industry for the R & D, production and sales of pharmaceutical intermediates is the basic chemical raw material industry, and the downstream industry is the chemical bulk drug and chemical pharmaceutical preparation industry.